BCL2 and B-cell non-Hodgkin lymphoma: According to the WHO classification [22], a total of five (17.2%) patients were, therefore, reclassified as aggressive B-cell lymphoma with MYC, BCL2, and/or BCL6 rearrangements (DHL/THL).